###### Key messages

What is the key question?
=========================

-   Whether switching from continuous (automatic) positive airway pressure (CPAP/APAP) to bilevel PAP would be clinically beneficial in patients for whom initial therapy was deemed ineffective.

What is the bottom line?
========================

-   A switch to bilevel was associated with clinically and statistically significant improvements in PAP therapy adherence.

Why read on?
============

-   There are few data showing the benefits of bilevel PAP over standard CPAP/APAP in patients with obstructive sleep apnoea who are pressure intolerant.

Nasal continuous positive airway pressure (CPAP) is a highly efficacious therapy for obstructive sleep apnoea (OSA). However, poor adherence to therapy can limit the effectiveness of treatment.[@R1] Efforts to improve adherence to positive airway pressure (PAP) therapy are a key issue in OSA management. These include intensive support,[@R2] changes in interface, nasal decongestion, cognitive--behavioural therapy and patient engagement techniques.[@R3] Another option is to change the type of PAP mode, although existing data from observational studies and meta-analysis do not generally support the strategy of changing from one mode to another.[@R4] However, current evidence is flawed by unselected populations and/or small numbers. Our clinical experience suggests that patients who are pressure intolerant sometimes have a preference for use of either expiratory pressure relief or bilevel PAP modes in which a different pressure is provided during inspiration versus expiration. However, financial considerations can lead to questions regarding the value of switching patients to a more expensive device.

To our knowledge, there are few data showing the benefits of bilevel PAP over standard CPAP/automatic CPAP (APAP) in patients with OSA who are pressure intolerant. Therefore, we retrospectively investigated whether switching from CPAP/APAP to bilevel PAP would be clinically beneficial in patients for whom initial therapy was deemed ineffective. We used a big data approach in which records from individuals who had agreed to have their therapy device data stored using cloud-based technology were queried for potential changes in adherence.

We queried the AirView (ResMed) database for patients who were initiated on CPAP or APAP and switched to a bilevel PAP (VAuto or Spont mode) within the first 90 days after therapy initiation. The following device-derived parameters were determined before the switch (CPAP/APAP) and after the change to bilevel PAP: percentage of days with average daily PAP usage of ≥4 hours; average daily PAP usage; residual apnoea--hypopnoea index (as a measure of therapy effectiveness); leak; average PAP usage per session; percentage of patients achieving United States Center for Medicare and Medicaid Services (CMS) compliance criteria after switching to bilevel PAP therapy (CMS compliance is defined as device usage for ≥4 hours/night on 70% of nights in a consecutive 30-day period). These criteria are important because they need to be met for a health insurance provider to continue paying for the treatment device. Essentially, if a patient does not meet CMS criteria for insurance coverage, they will lose their PAP device. Patients had not reached the definition of CMS compliance before the switch so that we could measure how many did then qualify after the switch.

Between 1 January 2015 and 31 July 2016, a total of 1496 eligible patients (mean age 58.1±14.2 years) were identified from approximately 1.36 million patients; initial therapy was APAP in 62.3%, CPAP in 30.3%, and APAP and CPAP in 7.4%. The pathway for CMS reimbursement of bilevel PAP after switching from APAP or CPAP is shown in [figure 1](#F1){ref-type="fig"}. After switching, the bilevel PAP mode was VAuto in 52.2% of patients and Spont in 47.8%. Average 95th percentile pressure before the switch (CPAP/APAP) was 12.5±3.7 cmH~2~O; after the switch to bilevel, average 95th percentile inspiratory and expiratory positive airway pressures were 15.1±4.1 and 10.5±3.9 cmH~2~O, respectively. Switching to bilevel was associated with significant improvements in compliance and device metrics ([table 1](#T1){ref-type="table"}), regardless of bilevel PAP mode. Median average daily PAP usage improved by 0.9 h/day ([figure 2](#F2){ref-type="fig"}). The greatest improvement was seen in those with the lowest average 95th percentile pressure (range 4--10 cmH~2~O) with CPAP/APAP with an increase of 1.8 h/day, then the 10--15 cmH~2~O range with 0.8 h/day increase followed by the 15--20 cmH~2~O range with 0.7 h/day increase. Overall, 56.8% of patients who were non-compliant with CPAP/APAP achieved CMS compliance criteria after switching to bilevel PAP; the proportion of patients who achieved CMS criteria was 58.5% in the subgroup of patients switched by day 60 (59.9% of the total population) and 54.2% in the subgroup switched between day 61 and day 90 (40.1% of the total population).

###### 

Changes in compliance and device metrics

                                   Before switch (CPAP/APAP)   After switch (bilevel PAP)   Difference   P value
  -------------------------------- --------------------------- ---------------------------- ------------ ---------
  Average AHI                      4.9 (2.0, 11.8)             4.0 (1.7, 9.2)               --0.9        \<0.001
  Average median leak, L/min       5.0 (1.3, 11.3)             4.1 (1.1, 10.4)              --0.9        \<0.001
  \% Days with usage of ≥4 hours   52.7 (14.3, 86.9)           68.9 (27.8, 93.3)            +16.2        \<0.001

Values are median (IQR).

AHI, apnoea--hypopnoea index; APAP, automatic continuous positive airway pressure; CPAP, continuous positive airway pressure; PAP, positive airway pressure.
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These findings are the first to show that there may be potential benefit from switching to bilevel therapy from CPAP or APAP for patients who are struggling with PAP adherence. To the best of our knowledge, most prior studies in this area were small and based on determination of non-inferiority rather than superiority. The majority of existing literature has suggested that bilevel therapy is equivalent to CPAP. We know of only one small study that showed potential superiority with bilevel PAP therapy.[@R9] However, it focused on a proprietary technology and the study was small and showed only modest benefits.

In our study, a switch to bilevel was associated with clinically and statistically significant improvements in PAP therapy adherence with greatest improvements seen in those on lower pressures and those switched before day 60. The study was specifically designed around the US CMS PAP adherence criteria, which require ongoing use of PAP therapy for patients to keep the equipment. The goal was to identify strategies that could impact clinical care under current reimbursement pathways. As such, the observed improvement in adherence to therapy associated with a switch to bilevel PAP could allow a substantial proportion of patients (up to 57% in this study) who would otherwise not have met CMS criteria to keep their funded PAP device rather than have to discontinue or pay for therapy. Thus, there are clear benefits to patients who improve adherence in this context. Achieving CMS criteria means that patients are able to retain their funded PAP therapy and continue to benefit from treatment. If CMS criteria are not met and the patient does not choose to pay for therapy, they would have to go through the complete clinical pathway of physician consultation, sleep study, diagnosis and therapy initiation if they wanted to try again to access funded CPAP therapy.

Although our study had a number of strengths, we also acknowledge some limitations. It was not a randomised trial and therefore we cannot rule out the possibility that patients who switched to bilevel PAP were systematically different from those who did not. In addition, we cannot exclude the possibility that other adherence-improving measures were implemented at the time of the switch to bilevel PAP nor do we know the mechanisms of the benefit. In theory, frequent visits to a healthcare provider could have intangible benefits to patients that may be as important as the change in PAP technology. Given that patients were selected based on poor compliance, regression to the mean could also contribute to some of the improvements in compliance seen in our study. However, early device usage tends to predict longer-term usage, so the contribution of regression to the mean to the increase in device usage seen in our analysis may be small. Based on our study design and the nature of the de-identified database queried, we do not know specific details about our participants and cannot determine whether the observed benefits vary by factors such as age, race, gender or socioeconomic status. Thus, further research is also recommended in this area. Finally, we did not have the ability to assess major outcomes and therefore do not know whether the change to bilevel therapy had any beneficial effects on OSA-related symptoms or comorbidities. However, improvements in PAP device usage of at least 0.5 h/day have been defined as being clinically relevant.[@R9] Therefore, the 0.9 h/day improvement in device usage after a switch to bilevel PAP therapy in our study is considered likely to be associated with some benefits for patients.
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